AMICUS THERAPEUTICS, INC. — Board/Management Information 2014

Mar 3, 2014

*UNITED STATES*

*SECURITIES AND EXCHANGE COMMISSION*

*WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT PURSUANT TO*

*SECTION 13 OR 15(D) OF THE*

*SECURITIES EXCHANGE ACT OF 1934*

Date of Report (Date of earliest event reported): March 3, 2014

*AMICUS THERAPEUTICS, INC.*

(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-33497	71-0869350
(Commission File Number)	(IRS Employer Identification No.)

1 Cedar Brook Drive, Cranbury, NJ	08512
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\C901713\14-7219-1\task6592064\7219-1-ba.htm',USER='C901713',CD='Mar 3 09:25 2014'

*Item 8.01. Other Events.*

On March 3, 2014, Amicus Therapeutics, Inc. issued a press release announcing the appointment of Jay A. Barth, MD as the company’s Chief Medical Officer. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

*Item 9.01. Financial Statements and Exhibits.*

(d) Exhibits: The Exhibit Index annexed hereto is incorporated herein by reference.

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\C901713\14-7219-1\task6592064\7219-1-ba.htm',USER='C901713',CD='Mar 3 09:25 2014'

*SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ William D. Baird III
William D. Baird III
Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\C901713\14-7219-1\task6592064\7219-1-ba.htm',USER='C901713',CD='Mar 3 09:25 2014'

*EXHIBIT INDEX*

Exhibit No.	Description
99.1	Press Release dated March 3, 2014

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\C901713\14-7219-1\task6592064\7219-1-ba.htm',USER='C901713',CD='Mar 3 09:25 2014'